Table 2

Biomarker concentrations

OverallNSAP*Uncomplicated†Complicated‡OthersP values§
miR-122 (x104 copies/mL)
 Median1.810.905.722.261.13<0.001
 IQR0.54–7.00.41–2.230.97–16.850.75–7.860.42–4.42
 95% CI6.21 to 16.404.32 to 26.429.51 to 22.241.54 to 22.822.26 to 8.23
HMGB1 (ng/mL)
 Median2.342.082.602.292.700.584
 IQR1.34–3.551.26–3.501.30–4.671.44–3.371.18–4.16
 95% CI2.13 to 2.601.50 to 2.592.05 to 3.012.02 to 2.561.90 to 3.10
cck-18 (U/L)
 Median114.60100.33139.71111.35114.840.009
 IQR87.40–171.5375.05–135.4098.15–228.7187.17–171.8387.12–181.26
 95% CI105.02 to 123.6787.23 to 112.47121.82 to 168.56100.31 to 134.2495.27 to 125.78
flk-18 (U/L)
 Median202.99107.08322.55236.34205.54<0.001
 IQR102.63–450.5566.39–168.43133.43–662.04136.63–429.38101.81–462.56
 95% CI170.60 to 237.2478.90 to 149.70202.10 to 479.32184.91 to 304.06151.78 to 325.69
  • *Non-specific abdominal pain.

  • †Biliary colic, aseptic choledocholithiasis.

  • ‡Cholecystitis, cholangitis, gallstone pancreatitis.

  • §Kruskal-Wallis test and Dunn’s multiple comparison test.

  • cck-18, caspase-cleaved keratin-18; flk-18, full-length keratin-18; HMGB1, high-mobility group box 1; miR-122, microRNA-122; NSAP, non-specific abdominal pain.